Emerson has acquired Fluxa, to accelerate the speed to market for new therapies, drugs and vaccines. The acquisition builds on Emerson’s leading software and solutions portfolio and life sciences expertise. The acquisition of Fluxa’s PKM™ software will provide customers with a unique solution, integrated with Emerson’s industry-leading DeltaV™ control system and life sciences automation software, accelerating the development of new drug therapies into production. --------------------------------------------------------------------------------------------- Fluxa accelerates the speed to market for new therapies by helping drug development and manufacturing organizations harness the power of collaboration and data across sites, functions, and processes. Our flagship product, Scale-Up provides drug manufacturers with unprecedented collaboration across global sites and functions, reducing overall risk on costs and quality. Our software is user-focused, domain-specific, and built on the latest digital technologies.